News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vectura Group plc Bags Major U.S. Partner, GlaxoSmithKline (GSK) for Copy of Lung Drug in Deal Worth Up to $45 Million


8/3/2011 7:27:56 AM

Inhaled-drug specialist Vectura Group has struck a new U.S. partnership deal for its generic lung drug VR315, which is widely thought by analysts to be a copy of GlaxoSmithKline's top-selling Advair. The collaboration, development and licence agreement has been signed with a U.S. division of an undisclosed leading international pharmaceutical company, Vectura said on Wednesday. VR315 is a key product for the British group and a decision in March by Sandoz, the generic division of Novartis , to hand back U.S. rights to the drug was a serious setback. Sandoz is continuing to develop the medicine for the European market.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES